Sign in

    Sahil Dhingra

    Senior Equity Research Associate specializing in Healthcare at RBC Capital Markets

    Sahil Dhingra is a Senior Equity Research Associate specializing in Healthcare at RBC Capital Markets, where he covers pharmaceutical companies including Aurinia Pharmaceuticals. He is recognized for insightful analysis in earnings calls and reports, with a record of participating directly in covering key sector names and contributing to robust research output. Dhingra began his career as an Associate at JPMorgan India Pvt before joining RBC Dominion Securities, and has held his current role for nearly two years. He holds the Chartered Financial Analyst (CFA) designation and maintains professional credentials relevant to equity research.

    Sahil Dhingra's questions to Aurinia Pharmaceuticals (AUPH) leadership

    Sahil Dhingra's questions to Aurinia Pharmaceuticals (AUPH) leadership • Q1 2025

    Question

    Sahil Dhingra, on behalf of Doug Miehm, asked about the SG&A expense, which was lower than modeled, questioning if there were one-time items and how to think about the expense going forward. He also asked about the potential market impact of Roche's Gazyva on LUPKYNIS adoption, given its upcoming PDUFA date.

    Answer

    CFO Joe Miller explained that while there was a small stock-based compensation true-up, the SG&A was not otherwise unusual and reflects the benefit of the November restructuring, keeping the company on track for its $40M cash OpEx savings goal. On Gazyva, CEO Peter Greenleaf and CMO Dr. Greg Keenan welcomed more players to grow the market. They positioned LUPKYNIS as highly competitive due to its rapid speed of response, which aligns with new ACR guidelines, contrasting with the slower onset of B-cell agents.

    Ask Fintool Equity Research AI